Citius Oncology ships first international LYMPHIR order to Europe via NPPs

CITIUS ONCOLOGY, INC.

Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.
Access via Named Patient Programs (NPPs) in local countries; no EMA marketing authorization.
LYMPHIR FDA-approved Aug 2024 for relapsed/refractory CTCL; US commercial launch in Dec 2025.
Company continues US launch with progress on formulary access, payer coverage, and physician engagement.
CEO Leonard Mazur cites commitment to expanding patient access beyond the US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.